MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$2,293K
(80.61%↑ Y/Y)
Income tax expense
(benefit)
-$3,657K
(-160.99%↓ Y/Y)
Interest and other
income, net
$2,382K
(-46.17%↓ Y/Y)
Qelbree
$77,843K
(20.23%↑ Y/Y)
GOCOVRI
$35,240K
(14.83%↑ Y/Y)
Trokendi Xr
$9,479K
(-25.95%↓ Y/Y)
ONAPGO
$8,375K
APOKYN
$7,728K
(-48.40%↓ Y/Y)
Oxtellar XR
$7,422K
(-27.22%↓ Y/Y)
Manufactured Product Other
$4,666K
(-45.61%↓ Y/Y)
Loss before income
taxes
-$5,950K
(-2.04%↓ Y/Y)
Total other income
(expense), net
$2,382K
(-46.17%↓ Y/Y)
Product
$150,753K
(6.17%↑ Y/Y)
Royalty License And
Other Revenue
$29,309K
(274.03%↑ Y/Y)
Collaboration Revenue
$27,643K
Operating loss
-$8,332K
(18.76%↑ Y/Y)
Total revenues
$207,705K
(38.63%↑ Y/Y)
Total costs and
expenses
$216,037K
(34.96%↑ Y/Y)
Selling, general and
administrative
$125,173K
(39.17%↑ Y/Y)
Research and development
$39,438K
(46.46%↑ Y/Y)
Amortization of intangible
assets
$25,644K
(29.61%↑ Y/Y)
Cost of revenues
$23,391K
(48.39%↑ Y/Y)
Contingent consideration
loss
$2,391K
(-68.79%↓ Y/Y)
Back
Back
Income Statement
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
source: myfinsight.com